TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8475869

Group type: EXPERIMENTAL
Intervention: Extended-release gemfibrozil 1,200 mg once daily
Number of subjects: 655

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 655
Study: 3894608

Group type: EXPERIMENTAL
Intervention: Live attenuated bovine rotavirus vaccine strain RIT 4237
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 31562140

Group type: EXPERIMENTAL
Intervention: Protocolled practice nurse-led asthma care
Number of subjects: 180
Study: 30318515

Group type: EXPERIMENTAL
Intervention: Galunisertib-gemcitabine
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo-gemcitabine
Number of subjects: 156
Study: 26067078

Group type: EXPERIMENTAL
Intervention: Canned chickpea (200 g per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Raffinose (5 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control foods
Number of subjects: 12
Study: 21684626

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 96

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 96
Study: 20687863

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 15
Study: 18426261

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 15883316

Group type: EXPERIMENTAL
Intervention: AN1792 (225 microg) plus QS-21 (50 microg)
Number of subjects: 372

Group type: COMPARATOR
Intervention: CSF examination in antibody responders (n = 11)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 372
Study: 14562195

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination protocol (0-7-21 days) with combined hepatitis A/B vaccine (Twinrix(R))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard vaccination scheme (0-1-6 months) with combined hepatitis A/B vaccine (Twinrix(R))
Number of subjects: 0
Study: 10379125

Group type: EXPERIMENTAL
Intervention: Midwife-managed care (Group A)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Obstetrician-managed care (Group B)
Number of subjects: 1050
Study: 8818378

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Compulsion Checklist (CC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10-Item YBOCS plus the 4-item Disability scale
Number of subjects: 46
Study: 29193414

Group type: EXPERIMENTAL
Intervention: Cardiovascular health promotion intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study: 28404069

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 12 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) for 24 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) plus ribavirin (weight-based 1000 mg or 1200 mg) for 12 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Post-treatment (all groups)
Number of subjects: 267
Study: 23653143

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic intervention for managing behavioral symptoms
Number of subjects: 119
Study: 22633301

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (≤4.5 mmol/L)
Number of subjects: 6496

Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia (>8.3 mmol/L)
Number of subjects: 6496

Group type: COMPARATOR
Intervention: Normoglycemia (4.5-5.5 mmol/L)
Number of subjects: 6496

Group type: EXPERIMENTAL
Intervention: Hyperglycemic patients (>8.3 mmol/L)
Number of subjects: 6496
Study: 20881891

Group type: EXPERIMENTAL
Intervention: 1 mg anastrozole
Number of subjects: 72

Group type: COMPARATOR
Intervention: 20 mg tamoxifen
Number of subjects: 72
Study: 17387127

Group type: EXPERIMENTAL
Intervention: PCI with optimal medical therapy
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2287
Study: 15608427

Group type: EXPERIMENTAL
Intervention: Interleukin (IL) 2 preconditioning followed by vaccination with virus-modified autologous tumor cells
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaccination with virus-modified tumor cells
Number of subjects: 20
Study: 11880960

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg given by mouth 3 times per day for 2 days)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 10734323

Group type: EXPERIMENTAL
Intervention: Vecuronium infusion of 50 microg/kg/hour following a bolus dose of 0.1 microg/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Atracurium infusion of 400 microg/kg/hour following a bolus dose of 0.5 microg/kg
Number of subjects: 62
Study: 7485324

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Phenytoin (Dilantin)
Number of subjects: 54
Study: 2104067

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 0
Study: 33863

Group type: EXPERIMENTAL
Intervention: Nadolol once daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol four times daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nadolol once daily (extended treatment)
Number of subjects: 29
Study: 31469016

Group type: EXPERIMENTAL
Intervention: Robot-assisted correction of benign ureteral stricture
Number of subjects: 36
Study: 28640770

Group type: EXPERIMENTAL
Intervention: 1 vs. 1 (no sparring partner change)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 vs. 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 vs. 4
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 × 2 m ring size
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 × 4 m ring size
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 × 6 m ring size
Number of subjects: 20

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 20
Study: 25511354

Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy (TPbx)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Transrectal prostate biopsy
Number of subjects: 75
Study: 23881187

Group type: EXPERIMENTAL
Intervention: Peer-educator network intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 20236794

Group type: EXPERIMENTAL
Intervention: Vocal warm-up (WU) program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (30 minutes of vocal rest)
Number of subjects: 45
Study: 19449366

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Active control/usual care
Number of subjects: 2751
Study: 16436649

Group type: EXPERIMENTAL
Intervention: IM interferon beta‐1a (IFNbeta‐1a) 30 microg IM once weekly for up to 5 years
Number of subjects: 383

Group type: COMPARATOR
Intervention: Delayed treatment (placebo in CHAMPS)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: IM interferon beta‐1a (IFNbeta‐1a)
Number of subjects: 383
Study: 15522040

Group type: EXPERIMENTAL
Intervention: Standing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sitting
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supine lying
Number of subjects: 60
Study: 11163733

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg, n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 24
Study: 9233974

Group type: EXPERIMENTAL
Intervention: Specially designed, physiologic circumcision restraint chair
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pacifier dipped in 24% sucrose solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine hydrochloride
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (rigid plastic restraint board, standard DPNB, pacifier dipped in water)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels
Number of subjects: 80
Study: 8104270

Group type: EXPERIMENTAL
Intervention: Ramipril (1014 patients)
Number of subjects: 2006

Group type: COMPARATOR
Intervention: Placebo (992 patients)
Number of subjects: 2006
Study: 3943286

Group type: EXPERIMENTAL
Intervention: Ramp-function work test (20 W/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Step-function work test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ramp-function work test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ramp-function work test with steady-state period
Number of subjects: 12
Study: 31034856

Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2 iStent Trabecular Micro Bypass devices
Number of subjects: 152
Study: 29183844

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) twice daily (BID)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30) BID
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 263
Study: 26850806

Group type: EXPERIMENTAL
Intervention: Aromasticks containing essential oils (Bergamot, Sandalwood, Frankincense, Mandarin, Lavender)
Number of subjects: 65
Study: 24358145

Group type: EXPERIMENTAL
Intervention: Consistently insufficient 25(OH)D (GLL <50 nmol/l)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Consistently sufficient 25(OH)D (GHH >50 nmol/l)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Low levels of 25(OH)D
Number of subjects: 217
Study: 20961233

Group type: EXPERIMENTAL
Intervention: Targeted narrowband UVB phototherapy plus topical tetrahydrocurcuminoid cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Targeted narrowband UVB monotherapy
Number of subjects: 10
Study: 19008798

Group type: EXPERIMENTAL
Intervention: Pramipexole as an add-on therapy to L-DOPA and amantadin
Number of subjects: 78
Study: 15987706

Group type: EXPERIMENTAL
Intervention: Sum of ST-segment depression in all leads
Number of subjects: 5192

Group type: EXPERIMENTAL
Intervention: Sum of ST-segment depression
Number of subjects: 5192

Group type: EXPERIMENTAL
Intervention: Minimal inferior ST-segment elevation
Number of subjects: 5192

Group type: EXPERIMENTAL
Intervention: Anterior ST-segment elevation
Number of subjects: 5192

Group type: EXPERIMENTAL
Intervention: Extent of ST-segment depression
Number of subjects: 5192

Group type: EXPERIMENTAL
Intervention: Peak levels of creatine kinase during index episode of ACS
Number of subjects: 5192
Study: 11863119

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVC) pulse therapy (0.75 - 1.0 g/m2 body surface area) combined with oral corticosteroid (up to 1 mg/kg/day) for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Double‐filtration plasmapheresis (DFPP) combined with corticosteroid (up to 1 mg/kg/day) performed 1-2 times weekly for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 healthy individuals)
Number of subjects: 20
Study: 10491062

Group type: EXPERIMENTAL
Intervention: Frozen cultured human allogenic epidermal sheets
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard dry dressing
Number of subjects: 10
Study: 8580576

Group type: EXPERIMENTAL
Intervention: Liver-failure diet containing well-polished rice
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard liver-failure diet containing conventionally processed rice
Number of subjects: 3
Study: 2123914

Group type: EXPERIMENTAL
Intervention: Isosorbide 5-mononitrate (Is-5-Mn), 40 mg b.i.d. for 3 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7013895

Group type: EXPERIMENTAL
Intervention: Povidone iodine (Disadine DP)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Povidone iodine (Disadine DP) on contaminated wounds
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (contaminated wounds)
Number of subjects: 153
Study: 30738433

Group type: EXPERIMENTAL
Intervention: Zaltoprofen 480 mg/day for 48 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (similar dosages without zaltoprofen)
Number of subjects: 40
Study: 31161196

Group type: EXPERIMENTAL
Intervention: Plasma copper (per SD increment)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Plasma copper (quartile 4 ≥ 117.0 μg/dL)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Plasma copper
Number of subjects: 1236
Study: 28601167

Group type: EXPERIMENTAL
Intervention: Theory-based intervention targeting attitude towards restrictive dietary behaviors
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nutrition education (3 weekly 60-minute sessions)
Number of subjects: 70
Study: 25440281

Group type: EXPERIMENTAL
Intervention: Risk stratification score (RSS) based on multivariable logistic regression model incorporating 18 covariates; assigned values based on odds ratios (ORs).
Number of subjects: 10963

Group type: EXPERIMENTAL
Intervention: Risk model's predicted rates of renal failure.
Number of subjects: 10963
Study: 23526069

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG) alone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG) with omentectomy
Number of subjects: 31
Study: 21777463

Group type: EXPERIMENTAL
Intervention: Training, feedback, and tailored interventions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Training and feedback
Number of subjects: 22
Study: 18336986

Group type: EXPERIMENTAL
Intervention: Direct technique (G1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indirect technique (G2)
Number of subjects: 20
Study: 15983814

Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (SH) eyedrops
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate (SH) eyedrops
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 13
Study: 12627702

Group type: EXPERIMENTAL
Intervention: 2% commercial chlorhexidine solution (Cav Clean) applied for 40 seconds after acid etching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid for 15 seconds (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid gel containing 2% digluconate of chlorhexidine (Cond AC) for 15 seconds (Group III)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 9093237

Group type: EXPERIMENTAL
Intervention: Supportive care for anemia including erythropoietin and red blood cell transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of myeloid growth factors G-CSF and GM-CSF for neutropenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy for immune-mediated thrombocytopenia including zidovudine, corticosteroids, IVGG, and splenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet transfusions for thrombocytopenia caused by decreased production
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No specific therapy for asymptomatic hypergammaglobulinemia and lupus anticoagulants
Number of subjects: 0
Study: 8344335

Group type: EXPERIMENTAL
Intervention: [1‐14C]leucine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [4,5‐3H]leucine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [1‐14C]alpha‐ketoisocaproate (KIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [4,5‐3H]KIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [3H]leucine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [3H]KIC
Number of subjects: 0
Study: 3579357

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b (1 X 10(6) U per site, intralesional)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (intralesional)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b (5 X 10(6) U, intramuscular)
Number of subjects: 11
Study: 29076028

Group type: EXPERIMENTAL
Intervention: BI 425809 (doses: 0.5, 1, 2, 5, 10, 25, 50, 100, 150 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BI 425809 (25 mg tablet)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 26634389

Group type: EXPERIMENTAL
Intervention: Autonomous motivational priming
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neutral motivational priming
Number of subjects: 42
Study: 25226476

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study: 21925260

Group type: EXPERIMENTAL
Intervention: Single injection of lipopolysaccharide (LPS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 20
Study: 20857862

Group type: EXPERIMENTAL
Intervention: Conventional visual scoring of sleep stages and EEG spectral analysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EEG spectral analysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Conventional scoring and EEG spectral analysis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 90
Study: 18078449

Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin (5 mg)
Number of subjects: 51
Study: 16759445

Group type: EXPERIMENTAL
Intervention: Surgical clot removal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of tissue plasminogen activator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guglielmi detachable coils (GDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clipping cases
Number of subjects: 0
Study: 12846543

Group type: EXPERIMENTAL
Intervention: 1% halothane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.5% isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous anesthesia drugs
Number of subjects: 60
Study: 11209536

Group type: EXPERIMENTAL
Intervention: 37.5 IU recombinant FSH
Number of subjects: 15

Group type: COMPARATOR
Intervention: 50 IU recombinant FSH
Number of subjects: 15
Study: 8673559

Group type: COMPARATOR
Intervention: Class I (80.05% of the population sample)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Classes II, III, and IV (19.95% of the population)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Classes III and IV (10.85% of the population)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Classes III and IV
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Classes II, III, and IV
Number of subjects: 2000
Study: 2649308

Group type: EXPERIMENTAL
Intervention: Diuretic with usual diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic with weight loss diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic with low sodium/high potassium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker with usual diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker with weight loss diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker with low sodium/high potassium diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with usual diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with weight loss diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with low sodium/high potassium diet
Number of subjects: 0
Study: 329858

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2-5 mg twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30923873

Group type: EXPERIMENTAL
Intervention: Increased physical activity (leg kicks for 1 hour) in young individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced activity (2 weeks immobilization of one leg) in young individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Old tendons
Number of subjects: 0
Study: 28873749

Group type: EXPERIMENTAL
Intervention: 0.06mg/kg norbixin (NBIX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.2mg/kg bixin (BIX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-calorie meal without carotenoid (placebo)
Number of subjects: 12
Study: 25936724

Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses across three dose levels)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AERAS-402 (three doses at the highest dose level)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AERAS-402 (two doses)
Number of subjects: 206
Study: 23730991

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (achieved BP ≤140/90 mm Hg)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment (achieved BP ≤150/90 mm Hg)
Number of subjects: 724
Study: 21233810

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 88

Group type: COMPARATOR
Intervention: No pioglitazone
Number of subjects: 88

Group type: COMPARATOR
Intervention: No resistance training
Number of subjects: 88
Study: 19672186

Group type: EXPERIMENTAL
Intervention: CR665 (0.36 mg/kg) administered intravenously over 1 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg) administered orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered intravenously and orally
Number of subjects: 0
Study: 22328063

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (Arco®) - single dose (125 mg artemisinin and 50 mg naphthoquine)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem®) - three-day regimen (20 mg artemether and 120 mg lumefantrine)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (Arco®)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem®)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study: 15516356

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study: 9658725

Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by transplantation (allogeneic or autologous)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 220